Scailyte AG

Scailyte AG develops an artificial intelligence platform for precision medicine. Its proprietary ScaiVision™ platform processes large-scale single-cell and spatial omics data, integrating with clinical outcomes. This identifies complex disease patterns and disease-driving cellular states, facilitating AI-driven single-cell medicine biomarker discovery.

Founded in July 2017 as an ETH Zurich spin-off, Scailyte AG was co-founded by Manfred Claassen, Peter Nestorov, Daniel Sonnleithner, and Dennis Göhlsdorf. Its genesis stemmed from the need to efficiently extract information from vast single-cell datasets, leveraging algorithms for biomarker discovery. Peter Nestorov serves as CEO, Manfred Claassen as Chief Scientific Advisor.

Scailyte's platform is utilized by pharmaceutical and biotechnology companies, supporting biomarker discovery and drug development in precision medicine. The long-term vision centers on earlier disease identification through its AI-powered single-cell analysis. Scailyte aims to unlock multi-omics data and artificial intelligence potential, improving patient outcomes and delivering more effective diagnostics and therapies.

High-Level Overview

Scailyte AG is a clinical-stage precision medicine company that develops diagnostic and companion diagnostic (CDx) solutions using its proprietary AI platform, ScaiVision, to analyze single-cell and multi-omics data for biomarker discovery in oncology, autoimmunity, and complex diseases like IBD and endometriosis.[2][3][6] It serves pharmaceutical companies, clinical partners, and patients by identifying ultra-sensitive biomarkers for patient stratification, treatment response prediction, and personalized therapies, solving the problem of imprecise treatments in hard-to-treat diseases through explainable AI-driven insights from high-dimensional cellular data.[1][2][5] The company shows strong growth momentum, with Series A extended to USD 8 million, asset divestment to Hera Biotech, pilots turning into multi-year pharma partnerships, CHF 12M+ in public funding, and positioning for a Series B targeting CHF 100M total contract value (TCV) by 2027.[1][4]

Origin Story

Founded in 2017 as a spin-off from ETH Zürich, Scailyte emerged from pioneering research in single-cell technologies, -omics analytics, and AI to uncover disease patterns that traditional methods miss.[2][3][5] The core idea stemmed from combining high-quality single-cell datasets (e.g., scRNA-seq, TCR-/BCR-seq) with machine learning to discover biomarkers, initially validated through Innosuisse grants for projects with University Hospital of Zürich and Inselspital Bern.[4] Early traction included ETH spin-off recognition, hiring key roles like Director of Biomarker Discovery and Senior Data Scientist, securing a first S&P 100 customer, and clinical validation of ScaiVision (patent pending).[4] Pivotal moments feature partnerships like Turnstone Bio for TIL therapy biomarkers, a UK diagnostics co-development, and recent leadership additions like Chief Business Officer Tim Foley in 2024 to expand into the US market.[2][4]

Core Differentiators

• Explainable AI Platform (ScaiVision): Unbiased analysis of multimodal single-cell data (RNA-seq, CyTOF, spatial omics) delivers transparent, biologically interpretable biomarkers with high sensitivity/specificity, unlike black-box AI, enabling rapid translation to clinical assays.[2][6][9]
• Accelerated Discovery and Validation: Shortens R&D timelines via automation, supports parallel clinical programs, and has proven reproducibility through asset sales (e.g., endometriosis to Hera Biotech) and pharma pilots.[1][6][8]
• Clinical Network and Data Access: Leverages unique cohorts (e.g., CHF 12M-funded IBD program) and partnerships with top-10 pharmas, Inselspital, and investors for enriched datasets fueling an internal pipeline.[1][4]
• Focus on High-Impact Areas: Targets oncology, autoimmunity, and women's health with CDx for patient stratification, backed by world-leading advisors and a multidisciplinary team.[3][5][8]

Role in the Broader Tech Landscape

Scailyte rides the single-cell revolution in precision medicine, where AI meets multi-omics to unlock complex disease drivers amid surging demand for personalized therapies in oncology and autoimmunity.[1][2][6] Timing is ideal as single-cell tech enters clinical trials, with market forces like exploding omics data volumes (e.g., Tempus AI's model) and pharma's push for biomarkers favoring AI platforms that deliver 10x+ ROI via IP and partnerships.[1][4] It influences the ecosystem by divesting assets (e.g., to Hera Biotech), enabling TIL therapies (Turnstone), and scaling via grants/public funds, accelerating translation from research to diagnostics while setting standards for explainable AI in biotech.[4][8]

Quick Take & Future Outlook

Scailyte is primed for Series B funding to expand its pharma business, negotiating LOIs with top players on IBD and beyond, projecting 5x-10x ROI through strategic acquisition by 2027.[1] Trends like multimodal data integration, AI explainability mandates, and US market entry (via new CBO) will propel its pipeline of diagnostics/CDx, potentially consolidating leadership in single-cell precision medicine.[2][6] As it scales from ETH spin-off to global player, Scailyte could redefine biomarker discovery, ensuring the right treatment reaches the right patient and transforming outcomes in untreatable diseases—echoing its mission to pioneer clinical impact from cellular insights.[2]